A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Naïve Subjects With Chronic HCV GT1 and GT3 Infection

Trial Profile

A Phase II Open-Label Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172, MK-8742, and Sofosbuvir in Treatment-Naïve Subjects With Chronic HCV GT1 and GT3 Infection

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Mar 2017

At a glance

  • Drugs Elbasvir/grazoprevir (Primary) ; Ribavirin; Sofosbuvir
  • Indications Hepatitis C
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms C-SWIFT
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 18 Mar 2017 Results assessing antiviral effect of Zepatier and sofosbuvir using viral dynamics model, presented at the 118th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics
    • 22 Oct 2016 Results assessing efficacy and safety published in the Hepatology.
    • 17 Apr 2016 Re-treatment final results (n=25) presented at The International Liver Congress™ 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top